Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- UBS analyst Marcus Cole initiated coverage on Amrize Ltd AMRZ with a Neutral rating and announced a price target of $53. Amrize shares closed at $51.99 on Monday. See how other analysts view this stock.
- Rosenblatt analyst Chris Brendler initiated coverage on Galaxy Digital GLXY with a Buy rating and announced a price target of $25. Galaxy Digital shares closed at $18.47 on Monday. See how other analysts view this stock.
- Guggenheim analyst Seamus Fernandez initiated coverage on Amylyx Pharmaceuticals, Inc. AMLX with a Buy rating and announced a price target of $17. Amylyx Pharmaceuticals shares closed at $5.02 on Monday. See how other analysts view this stock.
- Jefferies analyst Maury Raycroft initiated coverage on Cardiff Oncology, Inc. CRDF with a Hold rating and announced a price target of $3.5. Cardiff Oncology shares closed at $3.16 on Monday. See how other analysts view this stock.
Considering buying AMLX stock? Here’s what analysts think:
Advertisement
Read This Next:
Photo via Shutterstock
Loading…
Loading…
AMLXAmylyx Pharmaceuticals Inc
$5.285.18%
Stock Score Locked: Edge Members Only
Benzinga Rankings give you vital metrics on any stock – anytime.
Edge Rankings
Momentum
96.69
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date ▲▼ |
ticker ▲▼ |
name ▲▼ |
Price Target ▲▼ |
Upside/Downside ▲▼ |
Recommendation ▲▼ |
Firm ▲▼ |
---|
Analyst Calendar
Join Benzinga Edge and unlock all the major upgrades, downgrades, and changes to the market’s most accurate analysts.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Already a member?Sign in